A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
Status:
Completed
Trial end date:
2014-05-30
Target enrollment:
Participant gender:
Summary
This is a Phase 4, open, prospective, non-interventional, multicenter trial for previously
treated adult participants with relapsed/refractory follicular lymphoma (FL). Eligible
participants with FL will receive 6-8 infusions of induction standard regimen of rituximab
plus chemotherapy. Participants with complete or partial remission at end of induction will
be assigned to maintenance therapy with rituximab once every 3 months for a maximum of 2
years or until relapse. The choice of the treatment regimen will be established on a per
center basis, according to the standard in use in the country and in the center, and each
center will use the same regimen through the study. Participants will be followed up for
safety and efficacy evaluation in accordance with routine practice.